Kratom Analog Scheduling Hits Botanical Supplements | Seller Compliance
- DOJ Schedule I listing of MGM-15, MGP1 and MGM-16 puts cat's claw and kratom-adjacent SKUs under heightened US compliance review
Overview
The news reports that San Francisco health officials linked a fatal overdose in a 37-year-old man to a cat's claw supplement containing MGM-15, a lab-made analog of 7-hydroxymitragynine (7-OH), sold under the Script Botanicals x Maui Labs brand at gas stations. The U.S. Department of Justice placed MGM-15, MGP1 and MGM-16 in Schedule I in August, and Utah officials tied MGP1 and MGM-15 to four deaths statewide. For US-bound sellers of botanical supplements, the signal is clear: any SKU whose label does not match its tested contents now carries federal scheduling, product removal and liability exposure.
Label-to-content mismatch is now the primary enforcement trigger. The victim's package contained four 100-mg tablets of uncaria tomentosa extract, yet officials said the product was marketed as cat's claw without disclosing MGM-15. The death was ruled an accident caused by toxic effects of kratom alkaloids. On Amazon Seller Central, TikTok Shop and Shopify storefronts, listings that describe a single botanical while containing an undisclosed analog are the highest-risk profile, and platforms are likely to tighten ASIN-level ingredient verification and restricted-keyword screening.
Specifically for sellers, the operational cost of compliance is front-loaded. Industry practice for a third-party botanical identity and potency test with scheduled-analog screening typically runs about $300-800 per SKU per batch, with turnaround of roughly 5-10 business days. Sellers should maintain certificates of analysis per lot, reconcile them against Supplement Facts panels, and avoid mixing kratom-adjacent extracts in the same warehouse bins as cat's claw inventory. Sellers without this documentation may see listing suppression, Buy Box loss, or account-level review, which can take a high-volume SKU offline for weeks. Industry data suggests compliance gaps in low-price botanical listings are where most delistings concentrate.
Looking at the enforcement trajectory, the DOJ has warned that MGM-16, not yet confirmed in public circulation, could emerge as a substitute, which implies further scheduling actions are plausible within the next 1-3 months. Similar analog-driven scheduling cycles historically have produced a wave of product removals within one to two quarters. Market elimination for non-tested, gas-station-style botanical SKUs could plausibly reach 30-50% of sellers in this niche, while sellers with third-party COAs and clean labels may capture displaced demand. Sellers should monitor DEA Federal Register notices and state warnings from Utah and Washington as leading indicators.
Questions 6
How can sellers verify their botanical supplements are free of scheduled 7-OH analogs?
Sellers should commission third-party laboratory testing for identity, potency and scheduled-analog screening on each production lot. Industry practice typically costs about $300-800 per SKU per batch with 5-10 business day turnaround. Retain certificates of analysis and reconcile them against the Supplement Facts panel before every listing refresh.
Why does the MGM-15 scheduling matter for cat's claw sellers on Amazon and Shopify?
The DOJ placed MGM-15, MGP1 and MGM-16 in Schedule I in August, meaning any cat's claw or botanical SKU containing these analogs is an unlawful controlled substance regardless of its label. The San Francisco case showed a four-tablet package of 100-mg uncaria tomentosa extract that tested positive for MGM-15 while being marketed as cat's claw. Sellers on Amazon Seller Central or Shopify should expect listing suppression and possible account review if undisclosed analogs are found.